Resverlogix’s BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits

NEXT STORY
Veterinary Therapeutics Market to Grow at 5.8% CAGR, Driven by Recent Developments in Veterinary Drugs, says Fortune Business Insights
PREV STORY
ADMA Biologics Receives FDA Approval for License Transfers for BIVIGAM® and Nabi-HB®
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis erzielt im dritten Quartal starkes Wachstum und treibt Innovationen wie fortschrittlicheTherapieplattformen voran, um das zukünftige Wachstum zu beschleunigen

Der Nettoumsatz steigt um 6% (kWk[1], +3% USD), vor allem dank folgender Beiträge: Cosentyx erzielt ...

author_avatar
NASDAQ Market News

Ascendis Pharma A/S Reports First Quarter 2018 Financial Results

- Continued execution and achievement of planned milestones across three wholly-owned clinical programs in ...

author_avatar
NASDAQ Market News

Helix BioPharma Corp. Initiates Enrollment of the Second Last Cohort in U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

RICHMOND HILL, Ontario, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: ...

author_avatar
NASDAQ Market News